Bella Shalamova
Family · Forest Hills, NYNPI 1861850513
Payments from drug & device makers
Across 410 payments — averaging $24.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Harmony Biosciences LLC$1K
- Pfizer$494
- Argenx US, Inc.$477
- Neurocrine Biosciences, Inc.$416
- Biogen$394
- plus $5K from 41 others
What the payments were for
- Food & beverage$9,91498%
- Education$1532%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,067 in reported general payments places this provider in the 95th percentile of 8,883 family providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 79 | $156,124 |
| IngrezzaValbenazine Tosylate | 13 | $108,869 |
| UbrelvyUbrogepant | 51 | $77,453 |
| QuliptaAtogepant | 32 | $35,252 |
| NuedextaDextromethorphan Hbr/Quinidine | 19 | $28,823 |
| OngentysOpicapone | 11 | $9,846 |
| Aimovig AutoinjectorErenumab-Aooe | 12 | $8,321 |
| Ajovy SyringeFremanezumab-Vfrm | 11 | $7,714 |
| Duloxetine Hcl | 14 | $5,011 |
| Doxepin Hcl | 16 | $3,211 |
| Levetiracetam | 83 | $2,755 |
| Gabapentin | 256 | $2,538 |
| Carbamazepine | 27 | $2,531 |
| Lidocaine | 22 | $1,657 |
| Donepezil Hcl | 171 | $1,622 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $494 | $156,12479 claims |
| Neurocrine Biosciences, Inc.Ingrezza, Ongentys | $416 | $118,71424 claims |
| AbbVieUbrelvy, Qulipta | $2,189 | $112,70583 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $47 | $28,82319 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,883 family providers in New York.
Other family in Forest Hills
- Christina NalboneNew York$197K
- Casey GrilloNew York$191K
- Suzanne WilsonIthaca$179K
- Jonathan LesuerSyracuse$172K
- Sheri HillNorth Syracuse$165K
- Cathrine CurtinBronxville$155K
- Mary Sullivan-WhalenNew York$137K
- Sarah AljahmiRockville Centre$87K
- John de OcaStaten Island$86K
- Fara StrickerGlen Oaks$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.